We first evaluated the role of mTORC1 on protein synthesis in 1-LN prostate cancer cells stimulated with varying concentrations of α2M* and its sensitivity to the mTORC1 inhibitor rapamycin and PI 3-kinase inhibitors, wortmannin and LY294002 (Figure 1). This evidence concerns the gene A2M and prostate carcinoma.